These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6596028)

  • 1. A comparative study of acute toxicity of drugs used during anticancer therapy in healthy and tumor-bearing mice.
    Scorza Barcellona P; Campana A; Rossi V; Corradino C; Silvestrini B
    Arch Toxicol Suppl; 1984; 7():90-3. PubMed ID: 6596028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of N-(o-methoxyphenyl)-maleimide on 5-fluorouracil cytotoxicity in Ehrlich (ascites) carcinoma.
    Ambaye RY; Indap MA
    Cancer Lett; 1991 Apr; 57(1):21-6. PubMed ID: 1902758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
    Holm B; Jensen PB; Sehested M
    Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of antineoplastic activity of cyclophosphamide by Alstonia scholaris in the Ehrlich ascites carcinoma-bearing mice.
    Jagetia GC; Baliga MS
    J Exp Ther Oncol; 2003; 3(5):272-82. PubMed ID: 14641813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of anti-tumor efficacy of injectable Centchroman in mice bearing Ehrlich ascites carcinoma.
    Shenoy BD; Udupa N; Kamath R; Devi PU
    Indian J Physiol Pharmacol; 1999 Apr; 43(2):259-62. PubMed ID: 10365323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic activity of pretazettine on Ehrlich ascites carcinoma: adjuvant effect on standard drugs in ABC regimen.
    Furusawa E; Lum MK; Furusawa S
    Chemotherapy; 1981; 27(4):277-86. PubMed ID: 7249790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new boron compound (guanidine biboric acid adduct) as an antitumour agent against Ehrlich ascites carcinoma in mice.
    Ghosh P; Sur B; Bag SP; Sur P
    Tumour Biol; 1999; 20(1):44-51. PubMed ID: 9858874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo assessment of toxicity and pharmacokinetics of methylglyoxal. Augmentation of the curative effect of methylglyoxal on cancer-bearing mice by ascorbic acid and creatine.
    Ghosh M; Talukdar D; Ghosh S; Bhattacharyya N; Ray M; Ray S
    Toxicol Appl Pharmacol; 2006 Apr; 212(1):45-58. PubMed ID: 16112157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-glycosyl Flavone from Urginea indica Inhibits Growth and Dissemination of Ehrlich Ascites Carcinoma Cells in Mice.
    Bevara GB; Kumar ADN; Koteswramma K L; Badana AK; Kumari S; Yarla NS; Malla RR
    Anticancer Agents Med Chem; 2017; 17(9):1256-1266. PubMed ID: 28044935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunologic response to the treatment of Ehrlich ascites tumor with titanocene dichloride.
    Köpf-Maier P; Hesse A
    J Cancer Res Clin Oncol; 1984; 108(2):254-5. PubMed ID: 6540782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of non-specific immunopotentiation with Corynebacterium liquefaciens and chemotherapy in tumor-bearing mice.
    Hattori T; Yamagata S
    Gan; 1975 Dec; 66(6):711-5. PubMed ID: 1225723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphological damage induced in vivo by Lonidamine on human metastatic cancer cells.
    De Martino C; Battelli T; Cavaliere R; Gallo Curcio C; Bellocci M; Manocchi D; Giustini L; Mattioli R; Rinaldi M; Di Filippo F
    Oncology; 1984; 41 Suppl 1():94-103. PubMed ID: 6717904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schedule-dependent interaction between vinblastine and cisplatin in Ehrlich ascites tumors in mice.
    Cemazar M; Auersperg M; Scancar J; Kirbis IS; Pogacnik A; Sersa G
    J Pharmacol Exp Ther; 2002 Jul; 302(1):337-43. PubMed ID: 12065735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor properties of boron complexes with hydroxy biguanide and salicyl hydroxamic acid against Ehrlich ascites carcinoma.
    Ghosh P; Bag SP; Sur B; Sur P
    Neoplasma; 1998; 45(2):68-72. PubMed ID: 9687884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprotection and enhancement of cancer chemotherapeutic efficacy of cyclophosphamide in mice bearing Ehrlich ascites carcinoma by diphenylmethyl selenocyanate.
    Chakraborty P; Sk UH; Bhattacharya S
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):971-80. PubMed ID: 19221751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Synthesis and toxic properties of organoarsenic compounds].
    Selivanova AS; Molodykh ZhV; Gamaiurova VS; Chernokal'skiĭ BD; Il'ina SV
    Dokl Akad Nauk SSSR; 1974 Sep; 218(2):493-6. PubMed ID: 4434832
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of phthalmustine, a new anticancer compound. II. Tumor inhibitory effect in murine Ehrlich ascites carcinoma and sarcoma-180.
    Bhattacharya S; Ghosh M; Sadhu U; Dutta S; Sanyal U
    Neoplasma; 1996; 43(3):209-13. PubMed ID: 8841510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Alstonia scholaris in enhancing the anticancer activity of berberine in the Ehrlich ascites carcinoma-bearing mice.
    Jagetia GC; Baliga MS
    J Med Food; 2004; 7(2):235-44. PubMed ID: 15298773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suramin enhancement of the chemotherapeutic actions of cyclophosphamide or adriamycin of intramuscularly-implanted Ehrlich carcinoma.
    Osswald H; Youssef M
    Cancer Lett; 1979 May; 6(6):337-43. PubMed ID: 455271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A tertiary sulfonium compound, dimethylsulfoniopropionate in green sea algae, completely suppresses crucial Ehrlich ascites carcinoma in mice.
    Nakajima K; Tsujiwaki S; Nakajima Y
    Anticancer Res; 2014 Aug; 34(8):4045-50. PubMed ID: 25075028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.